Bayer takes another swipe at Nexavar compulsory licence

15-10-2013

Bayer takes another swipe at Nexavar compulsory licence

Bayer has appealed against the Indian Intellectual Property Appellate Board (IPAB)’s compulsory licence (CL) order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.


Bayer, Nexavar, compulsory licence, Natco

LSIPR